SynNeurGe: A new biological classification system for Parkinson’s disease research

One of the things that makes developing effective treatments for Parkinson’s disease so challenging is its complexity.

Genentech and Sangamo to develop new therapies

The collaboration focuses on intravenously administered treatments targeting the tau gene, associated with Alzheimer’s disease and other tauopathies. Credit: Milad Fakurian on Unsplash. Sangamo Therapeutics

August 7, 2024

ArsenalBio secures $325m to develop cell therapy programmes

ArsenalBio’s pipeline comprises potential therapies being developed for treating solid tumours. Credit: shisu_ka/Shutterstock. ArsenalBio has closed an oversubscribed Series C financing round, securing $325m to

September 5, 2024

Light pollution may elevate Alzheimer’s risk

Outdoor light at night could be a significant risk factor in Alzheimer’s disease, according to new research from Rush.

September 12, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.